

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG ELECTRONICS CO., LTD., SAMSUNG ELECTRONICS
AMERICA, INC., FOSSIL GROUP, INC., FOSSIL STORES I, INC.,
FOSSIL PARTNERS, L.P., OURA HEALTH OY, and
ONEPLUS TECHNOLOGY (SHENZHEN) CO., LTD.,
Petitioner,

v.

OMNI MEDSCI, INC.,
Patent Owner.

IPR2025-01250 (Patent 9,651,533 B2)
IPR2025-01251 (Patent 10,874,304 B2)¹

Before LINDA E. HORNER, KEN B. BARRETT, KARA L.
SZPONDOWSKI, and SCOTT B. HOWARD, *Administrative Patent Judges*.²

BARRETT, *Administrative Patent Judge*.

ORDER
Granting Petitioner's Motion to Seal
37 C.F.R. § 42.54

¹ This Order addresses the same Motion filed in the above-identified proceedings. Therefore, we exercise our discretion to issue one order in each proceeding. The parties are not authorized to use this caption style.

² This is not an expanded panel decision. A three-judge panel presides over each proceeding.

I. INTRODUCTION

On February 3, 2026, the Director instituted *inter partes* review of U.S. Patent Nos. 9,651,533 B2 (“the ’533 patent”) and 10,874,304 B2 (“the ’304 patent”). Paper 19.³ On July 9, 2026, the Board entered the Board’s Default Protective Order (Exhibit 2119) and granted Patent Owner Omni MedSci, Inc.’s Motion to Seal that was filed in conjunction with its Response. Paper 33 (“Decision” or “Dec.”). The Board sealed: (i) the unredacted Response (IPR2025-01250, Paper 29; IPR2025-01251, Paper 28), (ii) the unredacted Declaration of Mohammed N. Islam, Sc.D. (Exhibit 2043, both original and corrected versions), and (iii) certain exhibits referenced therein (Exs. 2101–2107) (collectively, “the Confidential Materials”). Dec. 6.

On July 31, 2026, Samsung Electronics Co., Ltd., Samsung Electronics America, Inc., Fossil Group, Inc., Fossil Stores I, Inc., Fossil Partners, L.P., Oura Health Oy, and OnePlus Technology (Shenzhen) Co., Ltd. (collectively, “Petitioner”) filed a Motion to Seal that seeks to seal: (1) the unredacted Petitioner’s Reply (Paper 36 “Reply”), (ii) the unredacted Declaration of Brian Anthony, Ph.D. (Exhibit 1124 or “Anthony Reply Declaration”); and (iii) the deposition transcript of Igor Efimov, Ph.D. (Exhibit 1127 or “Efimov Deposition Transcript”), filed concurrently with the Reply. Paper 38 (“Motion” or “Mot.”). Petitioner conferred with Patent Owner, and Patent Owner does not oppose Petitioner’s Motion. Mot. 7–8.

The Board may, for good cause, issue an order to protect a party or person from disclosing confidential information. 37 C.F.R. § 42.54(a). Such

³ Unless otherwise indicated, we cite the papers and exhibits in IPR2025-01250.

IPR2025-01250 (Patent 9,651,533 B2)
IPR2025-01251 (Patent 10,874,304 B2)

protection includes entry of “an order to protect a party or person from disclosing confidential information, including . . . the following: . . .

(7) Requiring that a trade secret or other confidential research, development, or commercial information not be revealed or be revealed only in a specified way.” *Id.*

For the reasons given below, we determine Petitioner has established good cause to seal confidential information in the Reply (Paper 36), Anthony Reply Declaration (Ex. 1124), and Efimov Deposition Transcript (Ex. 1127). We also find the public, redacted versions of the Reply (Paper 37), Anthony Reply Declaration (Ex. 1138), and Efimov Deposition Transcript (Ex. 1139) to be compliant with our rules.

II. DISCUSSION

Petitioner’s Reply addresses arguments by Patent Owner and testimony of Patent Owner’s technical expert, Dr. Igor Efimov, related to objective indicia of non-obviousness, including copying. Mot. 2; Reply 19–24. Specifically, the Reply discusses the Confidential Materials that Patent Owner filed under seal and deposition transcripts referencing these same Confidential Materials. *Id.*

We previously determined that these Confidential Materials contain confidential business communications and information that reflect “Omni MedSci’s proprietary technical and commercial information regarding its patented SNR-improvement techniques for wearable physiological sensors, as well as Omni MedSci’s confidential business communications with Samsung personnel.” Dec. 4. We further found that “concrete harm would result from public disclosure” of the Confidential Materials. *Id.* at 5.

IPR2025-01250 (Patent 9,651,533 B2)
IPR2025-01251 (Patent 10,874,304 B2)

We find that Petitioner genuinely needs to rely on the Confidential Materials at trial to address Patent Owner’s objective indicia arguments. We also find that Petitioner’s redactions in the publicly available versions of the Reply (Paper 37), Anthony Reply Declaration (Ex. 1138), and Efimov Deposition Transcript (Ex. 1139) are narrowly tailored to protect confidential information. Petitioner seeks to redact only the specific passages of the Reply, the Anthony Reply Declaration, and the Efimov Deposition Transcript that quote or characterize the protected content of the Confidential Materials. Mot. 5. Accordingly, we find Petitioner’s redactions are consistent with preserving “the strong public interest in having an open record.” *Argentum Pharm. LLC v. Alcon Research, Ltd.*, IPR2017-01053, Paper 27, 4 (PTAB Jan. 19, 2018) (informative) (citing 37 C.F.R. § 42.54(a)).

For the reasons given above, we determine Petitioner has established good cause to seal the requested documents.

III. ORDER

In consideration of the foregoing, it is hereby

ORDERED that Petitioner’s motion to seal the unredacted Reply (Paper 36), the unredacted Reply Declaration of Brian Anthony, Ph.D. (Exhibit 1124), and the unredacted Deposition Transcript of Igor Efimov, Ph.D. (Exhibit 1127) in IPR2025-01250, is granted; and

FURTHER ORDERED that Petitioner’s motion to seal the unredacted Reply (Paper 35), the unredacted Reply Declaration of Brian Anthony, Ph.D. (Exhibit 1124), and the unredacted Deposition Transcript of Igor Efimov, Ph.D. (Exhibit 1127) in IPR2025-01251, is granted.

IPR2025-01250 (Patent 9,651,533 B2)
IPR2025-01251 (Patent 10,874,304 B2)

FOR PETITIONER:

James L. Davis, Jr.
Hyun-Joong Kim
SHEPPARD, MULLIN, RICHTER & HAMPTON LLP
ct-samsungomnimedsci@sheppardmullin.com
jdavis@sheppardmullin.com
hykim@sheppardmullin.com

Jasjit S. Vidwan
Robert G. Pluta
MAYER BROWN LLP
jvidwan@mayerbrown.com
rpluta@mayerbrown.com

Jared A. Smith
Ricardo J. Bonilla
FISH & RICHARDSON P.C.
jasmith@fr.com
rbonilla@fr.com

Jack Shaw
CHERRY JOHNSON SIEGMUND JAMES PC
jshaw@cjsjlaw.com

FOR PATENT OWNER:

Jennifer Hayes
Daniel S. Stringfield
Timothy Maloney
Angelo J. Christopher
Benjamin R. Holt
Daniel Georgiev
NIXON PEABODY LLP
jenhayes@nixonpeabody.com
dstringfield@nixonpeabody.com
tmaloney@nixonpeabody.com
achristopher@nixonpeabody.com
bholt@nixonpeabody.com
dgeorgiev@nixonpeabody.com